The scale of the disparity is difficult to overstate. Adolescents and young adults, defined in this context as patients between the ages of 15 and 39, and older adults aged 60 and above remain markedly underrepresented in clinical trials despite decades of evidence that trial participation correlates with access to cutting-edge therapies and improved outcomes. The gap is even wider for patients from racially and ethnically minoritized communities, those from lower-income backgrounds, and those treated in community-based settings rather than large academic centers. For a disease category that includes more than 100 distinct blood cancer types, the consequences of this exclusion ripple across the entire research enterprise, limiting the generalizability of trial results and delaying the delivery of new treatments to the very populations that stand to benefit most.

The structural reasons behind these gaps are well documented but notoriously difficult to fix. Eligible patients are often identified late in the course of their care, after treatment decisions have already been made and enrollment windows have closed. Referral pathways between community oncology practices and academic research centers are frequently fragmented, forcing patients and providers to navigate a maze of administrative hurdles at precisely the moment when time is most scarce. Awareness of available trials remains low among both patients and frontline clinicians, and access to dedicated patient navigation services is uneven at best. These barriers compound one another, creating a system in which the patients most likely to benefit from novel therapies are the least likely to encounter them.

Blood cancers add a unique layer of urgency to this problem. Unlike many solid tumors, where patients may have weeks or months to weigh treatment options, blood malignancies such as acute leukemias often demand immediate therapeutic intervention. The clinical tempo leaves little room for the deliberate consideration of clinical trial opportunities, and patients who might otherwise enroll find themselves swept into standard treatment pathways before research options can even be discussed. Any intervention designed to improve trial access in this space must therefore operate faster than the disease itself, identifying eligible patients and surfacing trial options at the very beginning of the care journey rather than after treatment plans have crystallized.

The Columbia-led study will evaluate a coordinated, patient-centered intervention that combines three complementary components. The first is AI-assisted patient identification, using computational tools to scan clinical data and flag patients who meet eligibility criteria for active trials, a task that traditionally consumes enormous amounts of clinician time and is prone to human oversight. The second is streamlined provider support, designed to reduce the administrative burden on oncologists and nurses who wish to refer patients to research programs but lack the time or infrastructure to do so efficiently. The third is personalized patient navigation, pairing patients with trained navigators who can guide them through the logistical, financial, and informational barriers that often stand between eligibility and enrollment.

Together, these components are designed to help patients and healthcare teams identify clinical trial opportunities earlier in the treatment trajectory and to connect eligible individuals with research programs at both academic and community cancer centers. The intervention will be evaluated through Blood Cancer United’s Clinical Trial Support Center, a centralized public resource that will serve as the operational backbone of the study. By embedding the research within an existing national infrastructure, the investigators hope to generate findings that are immediately scalable rather than confined to a single institution or health system.

Eric Cooks, Ph.D., Senior Director of Equity in Access Programs at Blood Cancer United, framed the investment as a necessary step toward systemic change. According to Cooks, advancing equity in cancer care requires evidence-based solutions that can be implemented across healthcare settings to address disparities, and the Columbia study will test innovative approaches to connect more patients with potentially life-saving clinical trials while ensuring that advances in blood cancer research reach all communities, including those historically underrepresented in clinical research. The emphasis on cross-setting implementation reflects a growing recognition in the health services research community that interventions confined to elite academic centers, however effective, cannot close population-level gaps on their own.

The study’s focus on health services research, rather than basic or translational science, is itself significant. Health services research examines how care is organized, delivered, and accessed, asking not whether a treatment works but whether the systems surrounding it allow patients to benefit from it in the first place. In oncology, this lens has become increasingly central as the pace of therapeutic innovation outstrips the capacity of existing care infrastructures to deliver it equitably. A breakthrough therapy that never reaches the patients who need it most is, from a public health perspective, only half a breakthrough, and the Equity in Access Research Program was designed specifically to fund the kind of systems-level evidence needed to close that second half of the gap.

Since its launch in 2021, the program has awarded nearly $21 million in funding to support 16 high-impact health services research studies, making it one of the most substantial philanthropic investments in cancer care delivery science. Blood Cancer United has acknowledged support from AstraZeneca and Syndax for the program and related initiatives focused on reducing healthcare disparities in blood cancer care and treatment. The organization, which has evolved continuously since its founding in 1949 to serve people affected by all blood cancer types, funds research, offers free resources and personalized support, and advocates at state and national levels for more accessible and affordable healthcare.

The implications of the Columbia study extend well beyond blood cancer. If the combined model of AI-assisted identification, provider support, and patient navigation proves effective, the findings could inform policy and practice across the broader oncology landscape, offering a template for how health systems, professional societies, and policymakers approach trial access for other underserved populations. The ultimate goal, as the investigators and funders describe it, is to increase access to clinical trials, improve overall participation, and ensure that every patient, regardless of age, geography, income, or background, has the chance to benefit from the remarkable pace of cancer research advances. In a field where the next breakthrough is always in development, the question of who gets to receive it may prove as consequential as the science itself.

Subject of Research: Health services research on equitable clinical trial access for blood cancer patients

Article Title: Blood Cancer United invests $2.5 million in health services research to improve clinical trial participation

Article References: Blood Cancer United invests $2.5 million in health services research to improve clinical trial participation. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Blood Cancer United, clinical trials, health equity, blood cancer, patient navigation, Columbia University, adolescents and young adults, older adults, health services research, Equity in Access Research Program, cancer disparities, AI-assisted screening